UNASSIGNED: 7254 Background: The purpose of this study was to determine the safety and feasibility of a new accelerated chemoradiotherapy regimen consisting of hypofractionated concomitant boost radiotherapy and concurrent @entity3003 / @entity1311 for locally advanced @entity1149 ( @entity1149 ). METHODS: Radiotherapy (XRT) consisted of 60 Gy continuous course, over 4-4.5 weeks, via 3-dimensional conformal techniques. Once-daily treatments were used, but the large field (including gross @entity5 and selected elective nodal beds) was given a daily dose of 2-2.2 Gy, with a 0.8-1 Gy concomitant boost (field within a field) to the gross @entity5 . Weekly @entity3003 (AUC=2) and @entity1311 (50 mg/m2) were given during XRT; then two cycles of systemic-dose @entity3003 (AUC=6) and @entity1311 (100 mg/m2, 3 weeks out of 4) were planned. Additionally, the nutritional supplement @entity3264 (10 mg tid) was prescribed in an effort to decrease @entity2910 and @entity353 . RESULTS: Before the early closure of this study due to @entity137 , five @entity1 were enrolled, of whom four are evaluable for feasibility/ @entity137 (one @entity1 becamse very noncompliant shortly after enrollment and was found to have progression including brain metastases prompting hospice care). Acutely, no @entity1 had Grade 3+ nonhematologic @entity137 during concurrent chemo-XRT. However, @entity1503 was significant in the post-XRT consolidation phase, resulting in systemic chemotherapy dose reduction and/or discontinuation in 3 of 4 @entity1 . Two @entity1 experienced dose-limiting non-hematologic late chemoradiation @entity137 . This included one (Grade 4) @entity4501 which probably contributed to the @entity1 's @entity204 and one Grade 3-4 radiation pneumonopathy. Two @entity1 are dead of disease. Three @entity1 are alive without definite evidence of disease at 14, 20 and 21 months followup. CONCLUSIONS: Despite the use of 3-D conformal technology, this regimen of concomitant boost accelerated hypofractionated radiotherapy with concurrent and systemic chemotherapy was excessively toxic and not feasible. [Table: see text].

Unexpected excessive XXXX in a pilot study of accelerated conformal radiotherapy with concurrent chemotherapy for stage III @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity3264 :: ('D018698', 'Chemical') :: ['glutamine'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity4501 :: ('MESH:D014138', 'Disease') :: ['tracheoesophageal fistula'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'stage III non-small cell lung carcinoma'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity137 :: (MESH:D064420,Disease) :: ['toxicity']
